diabetes research News
-
The European Association for the Study of Diabetes celebrates in IFEMA MADRID its 60th Annual Meeting
The annual meeting of the European Association for the Study of Diabetes expects to maintain for its 60th edition the participation level of previous years, in which around 15,000 diabetologists and diabetes experts from 130 countries attended. The scientific programme will feature more than 1,200 sessions on the latest results in diabetes research by leading experts in the field. The congress ...
-
Georgia`s cyclists are pedaling hard to stop diabetes at local tour de cure event
Morgan Kendrick, President of Blue Cross and Blue Shield of Georgia, Appointed as Tour de Cure Executive Sponsor. In an effort to reduce the growing prevalence of diabetes, Blue Cross and Blue Shield of Georgia (BCBSGa), is the premiere sponsor of the Atlanta Tour de Cure® (TDC) on Sunday, May 15, 2011 at Bouckaert Farm in Fairburn, Georgia. This multi-faceted ride is the American Diabetes ...
-
Showcase
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
Top 5 Israeli innovations of the past decade
The Start-up Nation has made several ground breaking discoveries in the fields of technology, science, and innovation during the past decade.The first artificial pancreas – A potential cure for diabetes? In a possible future cure for diabetes, researchers at Betalin Therapeutics have engineered the first artificial pancreas. It can be inserted underneath the skin, without anesthesia and ...
-
Defymed at ATTD 2023
22-25 February (Berlin, Germany): Defymed at the Advanced Technologies and treatments for Diabetes. The purpose of the ATTD meeting is to highlight innovative technologies and treatments in diabetes management. It brings together developers of new technologies with the diabetes professionals and caretakers, researchers, industries, startup companies, investors, reimbursement authorities and ...
By Defymed
-
HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery
Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Doug Kawahara is joining HTI as Senior Advisor for AI/ML in Drug Discovery. Dr. Kawahara brings extensive experience in drug discovery and development to HTI. He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Previously, ...
-
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesizes multiple streams of existing evidence from ...
-
Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
-
Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz Supercharged Autologous Immunotherapy Platform
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company's ImmCelz® ...
-
Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical ...
-
Study Results Published in Diabetes Technology and Therapeutics Show Clinically Significant Improved Glycemic Control in People with Diabetes Using a Smart Blood Glucose Meter and Mobile App
LifeScan, a world leader in blood glucose monitoring, today announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth® connected Blood Glucose Meter with Mobile Diabetes Management Application, describing results from a retrospective analysis of real-world data ...
By LifeScan
-
Podimetrics Secures $45 Million Series C To Help At-Risk Providers and Health Plans Prevent Diabetic Amputations in High-Risk Patients
SOMERVILLE, Mass., March 24, 2022 — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced a $45 million Series C round led by D1 Capital Partners, along with two new investors, the Medtech Convergence Fund and an undisclosed strategic investor. Existing ...
-
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes. A multi-specific antibody, or ...
-
Obopay and Benevity partner to introduce new mobile giving solution
Obopay, Inc. (http://www.obopay.com/) and Benevity Social Ventures, Inc. (www.benevity.org), today announced an alliance to power a new text-to-donate offering that enables mobile donations and receipting for any registered charity in the United States. This innovative solution combines Obopay's instant mobile payment technology with expansive donation management, tax receipting and corporate ...
-
Research Finds Nearly 40% of Diabetes Patients who Suffer a Lower Extremity Amputation Endure Another Within Five Years
Reamputation Rates Have Not Improved Over Two Decades. SOMERVILLE, Mass., June 10, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which found patients with diabetes who have an amputation have a 37 percent chance of having reamputation within five years. The ...
-
Abbott named one of America`s most generous companies, sets company records for employee giving
Abbott has been recognized by The Chronicle of Philanthropy as one of the most generous companies in the U.S., ranking No. 5 out of 162 of the largest U.S. companies that participated in the magazine's survey of 2009 giving. In 2009, Abbott and the company's philanthropic foundation the Abbott Fund provided more than $580 million in grants and product donations. In 2010, Abbott's tradition of ...
-
Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab improved ...
By Osel Inc.
-
Research Finds All-Cause Hospitalizations are Nearly Three Times More Likely During a Diabetic Foot Ulcer Episode
SOMERVILLE, Mass., January 18, 2022 — Podimetrics, a virtual care support company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which compared the health of individuals during and after periods of diabetic foot ulceration — open sores or wounds on the foot, which commonly occur among those with diabetes and are the ...
-
BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies. February is set as American Heart Month since heart disease is the number one cause of death for most groups, affecting all ages, genders, and races. More than 600,000 Americans die from heart disease every year. The striking fact drives a great deal ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you